Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Released Exosomes Contribute to the Immune Modulation of Cord Blood-Derived Stem Cells

Hu W., Song X., Yu H., Sun J., Zhao Y.

Prospective Study on Type 1 Diabetes, Immune Modulation, Autoimmune Research, published in Front Immunol (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Immunol (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32161585
PMCID
PMC7052489
DOI
10.3389/fimmu.2020.00165
Citations
36

Abstract (original English)

Background: Clinical studies demonstrated the immune modulation of cord blood-derived stem cells (CB-SC) for the treatment of type 1 diabetes and other autoimmune diseases, with long-lasting clinical efficacy. To determine the molecular mechanisms underlying the immune modulation of CB-SC, the actions of exosomes released from CB-SC were explored in this study. Methods: Exosomes were isolated from CB-SC cultures using ultracentrifugation and confirmed with different markers. The activated T cells and purified monocytes from peripheral blood mononuclear cells (PBMC) were treated with CB-SC in the presence or absence of the purified exosomes, followed by functional and flow cytometry analysis of phenotypic changes with different immune cell markers. Results: CB-SC-derived exosomes displayed the exosome-specific markers including CD9, CD63, and Alix, at the size of 85.95 ± 22.57 nm. In comparison with the treatment of CB-SC, functional analysis demonstrated that the CB-SC-derived exosomes inhibited the proliferation of activated PBMC, reduced the production of inflammatory cytokines, downregulated the percentage of activated CD4 + T and CD8 + T cells, and increased the percentage of naive CD4 + T and CD8 + T cells. Using the fluorescence dye DiO-labeled exosomes, flow cytometry revealed that exosomes preferably bound to the monocytes in the PBMC, leading to an improvement of mitoc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesMonocytesCells, CulturedStem CellsFetal BloodHumansDiabetes Mellitus, Type 1Flow CytometryCoculture Techniques

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research